

Omadacycline (PTK 0796) Publications/Posters/Oral Presentations

Publications				
Date	Journal	Citation	First Author	Title
June 2020	Internal Med res Open J	5(2):1-6	Dubois	<i>In Vitro</i> and Intracellular Activities of Omadacycline against <i>Staphylococcus aureus</i> Isolates
May 2020	Diagnostic Micro. & Infect. Dis.	97(3):115054	Mendes	Omadacycline <i>In Vitro</i> Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Acquired Tetracycline Resistance Mechanisms
May 2020	J Antimicrob. Chemother.	Accepted, epub ahead of print	Pagano	<i>In vitro</i> Activity of Omadacycline and Levofloxacin against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Staphylococcus saprophyticus</i> in Human Urine Supplemented with Calcium and Magnesium
Apr 2020	Antimicrob. Agents and Chemother.	64(5):e01972-19	Dubois	<i>In Vitro</i> and Intracellular Activities of Omadacycline against <i>Legionella pneumophila</i>
Apr 2020	Antimicrob. Agents and Chemother.	64:e02265-19	VanScoy	Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline Against <i>Haemophilus influenzae</i> Using a One-Compartment <i>In Vitro</i> Infection Model
Apr 2020	Antimicrob. Agents and Chemother.	Accepted, epub ahead of print	Lakota	Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
Apr 2020	Antimicrob. Agents and Chemother.	64(5):e02488-19	Pfaller	Surveillance of Omadacycline Activity Tested Against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016-2018
Jan 2020	Antimicrob. Agents and Chemother.	64(2):e02058-19	Lepak	<i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Mouse Pneumonia Model
Dec 2019	J. Global Antimicrobial Resistance	19: 56-63	Huband	Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017
Oct 2019	Lancet Infect Dis.	19(10):1080-1090	O’Riordan	Once-daily Oral Omadacycline versus Twice-daily Oral Linezolid for Acute Bacterial Skin and Skin Structure Infections (OASIS-2): A Phase 3, Double-blind, Multicentre, Randomised, Controlled, Non-inferiority Trial
Oct 2019	Antimicrob. Agents and Chemother.	63:e00922-19	Darpo	A Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects

Publications				
Date	Journal	Citation	First Author	Title
Aug 2019	Clin. Infect. Dis.	69(Supplement 1): S1-5	Gallagher	Omadacycline: A Modernized Tetracycline
Aug 2019	Clin. Infect. Dis.	69(Supplement 1): S6-15	Karlowsky	Microbiology and Preclinical Review of Omadacycline
Aug 2019	Clin. Infect. Dis.	69(Supplement 1): S16-22	Rodvold	Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
Aug 2019	Clin. Infect. Dis.	69(Supplement 1): S23-32	Abrahamian	Omadacycline for Acute Bacterial Skin and Skin Structure Infections
Aug 2019	Clin. Infect. Dis.	69(Supplement 1): S33-39	Ramirez	Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice
Aug 2019	Clin. Infect. Dis.	69(Supplement 1): S40-47	Opal	An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
July 2019	American Health & Drug Benefits	12(4):168-176	Lodise	Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models
June 2019	Antimicrob. Agents and Chemother.	63:e00624-19	Lepak	<i>In vivo</i> Pharmacodynamics of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Murine Thigh Infection Model
May 2019	New England J of Medicine	380:2072-2074	Garrity-Ryan	Omadacycline for Bacterial Infections. Reply.
May 2019	Diagnostic Micro. & Infect. Dis.	94(1):78-80	Fluit	Minimal Inhibitory Concentration of Omadacycline and Doxycycline against Bacterial Isolates with Known Tetracycline Resistance Determinants
May 2019	Antimicrob. Agents and Chemother.	63:e02083-18	Overcash	Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1 Study
May 2019	Antimicrob. Agents and Chemother.	63:e02522-18	Shoen	<i>In vitro</i> Activities of Omadacycline against Rapidly Growing Mycobacteria
Feb 2019	American Health & Drug Benefits	12(1):Supplement 1, S1-S12	LaPensee	Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
Feb 2019	American Health & Drug Benefits	12(1):Supplement 2, S13-S24	LaPensee	Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections

Publications				
Date	Journal	Citation	First Author	Title
Feb 2019	New England J of Medicine	380:517-27	Stets	Omadacycline for Community-Acquired Bacterial Pneumonia
Feb 2019	New England J of Medicine	380:528-38	O’Riordan	Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
Feb 2019	Antimicrob. Agents and Chemother.	63:e01907-18	Kohlhoff	<i>In Vitro</i> Activity of Omadacycline against <i>Chlamydia pneumoniae</i>
Feb 2019	Antimicrob. Agents and Chemother.	63:e01581-18	Moura	Omadacycline Gut Microbiome Exposure does not Induce <i>Clostridium difficile</i> Proliferation or Toxin Production in a Model that Simulates the Proximal, Medial and Distal Human Colon
Dec 2018	American Health & Drug Benefits	11(9):449-459	LaPensee	Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
June 2018	Diagnostic Micro. & Infect. Dis.	91(2):179-183	Pfaller	Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Program (2014)
Apr 2018	Antimicrob. Agents and Chemother.	62:e02551-17	Goldstein	Omadacycline: Comparative <i>In vitro</i> Activity against Dog and Cat Bite Wound Isolates
Apr 2018	Antimicrob. Agents and Chemother.	62:e00047-18	Stapert	The <i>In Vitro</i> Activity of Omadacycline and Comparators Against Anaerobic Bacteria
Apr 2018	Antimicrob. Agents and Chemother.	62: e02327-17	Pfaller	Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016
Feb 2018	Antimicrob. Agents and Chemother.	62: e01487-17	Bundrant	Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple Dose Regimens
Feb 2018	Antimicrob. Agents and Chemother.	62: e02057-17	Berg	Pharmacokinetics and Safety of Omadacycline in Subjects With Impaired Renal Function
Feb 2018	Diagnostic Micro. & Infect. Dis.	90(2):143-147	Pfaller	Activity of Omadacycline Tested against <i>Streptococcus pneumoniae</i> from a Global Surveillance Program (2014)

Publications				
Date	Journal	Citation	First Author	Title
Sept 2017	Antimicrob. Agents and Chemother.	61: e01135-17	Gotfried	Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells in Healthy Adult Subjects
May 2017	Antimicrob. Agents and Chemother.	61: e02434-16	Steenbergen	<i>In Vitro</i> and <i>In Vivo</i> Activity of Omadacycline Against Two Biothreat Pathogens: <i>Bacillus anthracis</i> and <i>Yersinia pestis</i>
May 2017	Antimicrob. Agents and Chemother.	61: e02368-16	Lepak	<i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against <i>Streptococcus pneumoniae</i> in the Murine Pneumonia Model
May 2017	Antimicrob. Agents and Chemother.	61: e00018-17	Pfaller	Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011
May 2017	Xenobiotica	47:8, 682-696	Flarakos	Clinical Disposition, Metabolism and <i>In vitro</i> Drug–drug Interaction Properties of Omadacycline
Mar 2017	Antimicrob. Agents and Chemother.	61: e02411-16	Pfaller	Activity of Omadacycline and Comparator Agents When Tested against <i>Staphylococcus aureus</i> from a Surveillance Program Conducted in North America and Europe
Mar 2017	J. Clin. Pharmacol.	57(3): 321-327	Tzanis	Effect of Food on the Bioavailability of Omadacycline in Healthy Subjects
Jan 2017	Antimicrob. Agents and Chemother.	61: e01784-16	Lin	Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline Following a Single Intravenous or Oral Dose of ¹⁴C-omadacycline in Rats
Dec 2016	Bioorg. Med. Chem.	24(2016): 6409-6419	Tanaka	Discovery, Pharmacology, and Clinical Profile of Omadacycline, A Novel Aminomethylcycline Antibiotic
Dec 2016	Antimicrob. Agents and Chemother.	60(12): 7431-7435	Sun	A Randomized, Open-label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
Dec 2016	Antimicrob. Agents and Chemother.	60(12): 7502-7504	Waites	<i>In Vitro</i> Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas
Oct 2016	Future Microbiol.	11(11): 1421-1434	Villano	Omadacycline: Development of a Novel Aminomethylcycline Antibiotic for Treating Drug-Resistant Bacterial Infections

Publications				
Date	Journal	Citation	First Author	Title
Sept 2016	Antibiotics	5: 32	Heidrich	The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome
Sept 2016	Antimicrob. Agents and Chemother.	60(9): 5247-5253	Tanaka	<i>In Vitro</i> and <i>In Vivo</i> Assessment of Cardiovascular Effects with Omadacycline
Nov 2015	Antimicrob. Agents and Chemother.	59(11): 7044-7053	Honeyman	Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline
Mar 2014	Antimicrob. Agents and Chemother.	58(3): 1279–1283	Draper	Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline
Feb 2014	Antimicrob. Agents and Chemother.	58(2): 1127-1135	Macone	<i>In Vitro</i> and <i>In Vivo</i> Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline
Nov 2012	Antimicrob. Agents and Chemother.	56(11): 5650-5654	Noel	A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
Jul 8, 2020	MHSRS	MHSRS-20-00985	Besece	Treatment of Wound Infection using Omadacycline versus Linezolid: Pooled Results from Phase 3 Randomized, Double-blind, Multicenter Studies (OASIS-1 and -2)
Jul 8, 2020	MHSRS	MHSRS-20-00527	Huband	Activity of Omadacycline and Comparator Agents against Bacterial Isolates from Skin, Respiratory, and Wound Infections from United States and European Medical Centers (2014 – 2019)
May 5, 2020	ECCMID	5313	Rodriguez	Predicted Risk and Observed Occurrence of <i>Clostridioides difficile</i> Infection in Patients with Community-Acquired Bacterial Pneumonia Treated with Omadacycline or Moxifloxacin
May 5, 2020	ECCMID	2481	Lapensee	Self-Reported Health Status in Ambulatory Acute Bacterial Skin and Skin Structure Infection Patients Who Inject Drugs, Who Received Oral Therapy with Omadacycline or Linezolid

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
May 5, 2020	ECCMID	1764	Lapensee	Epidemiology of <i>Clostridioides Difficile</i> Infections Among Hospitalised Community-Acquired Pneumonia Patients Who Received Empiric Treatment with Ceftriaxone Plus a Macrolide
May 5, 2020	ECCMID	949	Huband	Activity of Omadacycline and Comparator Agents Against Bacterial Pathogens from the United States by Infection Type (2019)
Oct 2-6, 2019	IDWEEK	110	Sakoulas	Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
Oct 2-6, 2019	IDWEEK	665	Huband	In Vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections
Oct 2-6, 2019	IDWEEK	700	Pai	Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
Oct 2-6, 2019	IDWEEK	733	Bhavnani	Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Oct 2-6, 2019	IDWEEK	734	Friedrich	Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline With and Without a Loading Dose
Oct 2-6, 2019	IDWEEK	1561	Lakota	Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
Sept 3-6, 2019	ASM-ESCMID	T-21	Bhavnani	Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Cardiac Endpoints Using Clinical Study Data From Omadacycline (OMC)-Treated Patients
Sept 3-6, 2019	ASM-ESCMID	T-36	Curran	Bayesian Adaptive Dose-Response Studies in Complicated and Uncomplicated Urinary Tract Infection
Sept 3-6, 2019	ASM-ESCMID	W-62	Mendes	Omadacycline is Not a Substrate for Clinically Relevant β-Lactamase Enzymes
June 20-24, 2019	ASM Microbe	FRIDAY-CIV-155	Armstrong	Analysis of Pooled Microbiological Data from Two Phase 3 Studies of Omadacycline Treatment for Acute Bacterial Skin and Skin Structure Infections
June 20-24, 2019	ASM Microbe	FRIDAY-AAR-540	Huband	In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results
June 20-24, 2019	ASM Microbe	SATURDAY-AAR-608	Thwaites	Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and Gram-Negative Bacteria
May 14-17, 2019	SAEM	88	Pollack	Omadacycline Treatment of Acute Bacterial Skin and Skin Structure Infections in Intravenous Drug Users

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
Apr 13-16, 2019	ECCMID	O0304	Cornely	Safety and Efficacy of Omadacycline for Treatment of Community-acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections in Patients with Mild to Moderate Renal Insufficiency
Apr 13-16, 2019	ECCMID	O0306	Pai	Safety and Efficacy of Omadacycline for Treatment of Acute Bacterial Skin and Skin Structure Infections by Patient Body Mass Index
Apr 13-16, 2019	ECCMID	P1876	Huband	In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results
Apr 13-16, 2019	ECCMID	P1918	Pai	Safety and Efficacy of Omadacycline by Body Mass Index in Patients with Community-acquired Bacterial Pneumonia
Apr 13-16, 2019	ECCMID	P1943	Lakota	Omadacycline Pharmacokinetics: Impact of Comorbidities
Apr 13-16, 2019	ECCMID	P1944	Bhavnani	Assessment of Pharmacokinetics-Pharmacodynamics to Support Omadacycline Dosing Regimens for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSI)
Apr 13-16, 2019	ECCMID	P2011	Tzanis	Omadacycline Hepatic Safety: Integrated Analysis of Randomized Controlled Phase III Trials
Apr 13-16, 2019	ECCMID	P2288	LaPensee	Incidence of Emergency Department Visits and Hospitalizations after Outpatient Treatment with an Oral Antibiotic among Patients with Acute Bacterial Skin and Skin Structure Infections
Dec 2-6, 2018	ASHP	4-048	LaPensee	Cost-saving Opportunities Among Hospitalized Community-Acquired Pneumonia Patients Treated with Omadacycline, an Aminomethylcycline Antibiotic with IV and Oral Formulations, Compared to Ceftriaxone and Macrolide Therapy
Dec 2-6, 2018	ASHP	4-049	LaPensee	Cost-savings Analysis with Use of Omadacycline Among Hospitalized Community-Acquired Pneumonia Patients At Risk of Clostridium difficile Infection Being Treated with Moxifloxacin: Budget Impact Model Findings
Oct 3-7, 2018	IDWEEK	1347	Abrahamian	Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
Oct 3-7, 2018	IDWEEK	1356	Tzanis	Improvement in Quality of Life for Adults with Acute Bacterial Skin and Skin Structure Infections Following Treatment with Omadacycline or Linezolid
Oct 3-7, 2018	IDWEEK	1364	Mendes	Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSI Clinical Trials
Oct 3-7, 2018	IDWEEK	1374	Opal	Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
Oct 3-7, 2018	IDWEEK	1377	Mendes	Omadacycline <i>In Vitro</i> Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
Oct 3-7, 2018	IDWEEK	1462	Lodise	Hospital Admission Patterns in Adult Patients with Community-acquired Bacterial Pneumonia who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
Sept 15-19, 2018	ERS	PA5465	Ramirez	Impact of Age and Gender on Efficacy and Safety of Omadacycline versus Moxifloxacin in Community-acquired Bacterial Pneumonia
Sept 4-7, 2018	ESCMID-ASM	51	Shoen	<i>In vitro</i> activities of omadacycline against rapidly growing mycobacteria
June 7-11, 2018	ASM Microbe	SATURDAY-624	VanScoy	Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using A One-Compartment In Vitro Infection Model
June 7-11, 2018	ASM Microbe	SATURDAY-625	Bhavnani	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) for Streptococcus pneumoniae (SP) and Haemophilus influenzae (HI)
June 7-11, 2018	ASM Microbe	SATURDAY-626	Kohlhoff	<i>In Vitro</i> Activity of Omadacycline against Chlamydia pneumoniae
June 7-11, 2018	ASM Microbe	SATURDAY-627	Huband	Omacycline <i>In Vitro</i> Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the U.S. and Europe During the SENTRY Surveillance Program (2017)
June 7-11, 2018	ASM Microbe	SATURDAY-628	Lakota	Population Pharmacokinetic (PK) Analyses of Omadacycline Using Phase 1 and Phase 3 Data
June 7-11, 2018	ASM Microbe	SATURDAY-701	Armstrong	Efficacy of Omadacycline and Linezolid against Characterized Drug Resistant S. aureus from Combined Phase 3 ABSSSI Studies
May 18-23, 2018	ATS	A4458	Ramirez (presented by McGovern)	Early Clinical Response of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by PORT Risk Class: Results from the OPTIC Study
Apr 21-24, 2018	ECCMID	P0271	Cornely	Omacycline Gastrointestinal Effects-An Integrated Safety Analysis from the Phase 3 ABSSSI and CABP Studies
Apr 21-24, 2018	ECCMID	P0272	Garrity-Ryan	Efficacy of Omadacycline Versus Moxifloxacin in Treating Subjects From Different Geographic Regions With Community-acquired Bacterial Pneumonia (CABP)
Apr 21-24, 2018	ECCMID	P0273	O'Riordan	Effects of Oral Omadacycline Versus Oral Linezolid on Lesion Size and Local Signs of ABSSSI in the Phase 3 OASIS-2 Study

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
Apr 21-24, 2018	ECCMID	P0274	Bassetti	Efficacy of Oral Omadacycline Versus Linezolid for Treating Adult Subjects With ABSSSI: Analysis by Infection Type and Pathogen in the OASIS-2 Study
Apr 21-24, 2018	ECCMID	P0275	Torres	Omacycline Versus Moxifloxacin in the Treatment of Adults with Community-acquired Bacterial Pneumonia (CABP): Efficacy Analysis According to EMA Requirements
Apr 21-24, 2018	ECCMID	O0425	O’Riordan Presented by McGovern	A Phase-3 Randomized, Double-blind, Multi-centre Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects with ABSSSI (OASIS-2 Study)
Apr 21-24, 2018	ECCMID	P1821	Dubois	<i>In Vitro</i> Activity of Omadacycline Against Resistant <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i>
Apr 21-24, 2018	ECCMID	P1822	Huband	Activity of Omadacycline and Comparators against Gram-Positive and -Negative Clinical Isolates (including resistant organism subsets) Collected in 2017 from Patients in European Medical Centres: SENTRY Surveillance Programme Results
Apr 21-24, 2018	ECCMID	P1829	Dubois	<i>In Vitro</i> Activity of Omadacycline Against Resistant <i>Staphylococcus aureus</i>
Oct 16-19, 2017	AMCP Nexus	L1	LaPensee	Potential Cost-Saving Opportunities with Early Use of Omadacycline in Hospitalized Patients with ABSSSI with Inadequate Early Response to Vancomycin Plus Piperacillin-Tazobactam: Findings From a Decision-Analytic Budget Impact Model
Oct 4-8, 2017	IDWEEK	861	McGovern	Omacycline, the First Aminomethylcycline
Oct 4-8, 2017	IDWEEK	1223	Huband	<i>In Vitro</i> Activity of Omadacycline and Comparator Compounds against Gram-Positive Isolates Collected in the US During 2016 as Part of a Global Surveillance Program
Oct 4-8, 2017	IDWEEK	1531	Lepak	<i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against <i>Staphylococcus aureus</i> (SA) in the Murine Thigh Infection Model
Oct 4-8, 2017	IDWEEK	1834	File	Efficacy and Safety of Omadacycline in Chronic Kidney Disease (CKD) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis From the OASIS Trial
Oct 4-8, 2017	IDWEEK	1838	Wilcox	Efficacy and Safety of Omadacycline in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and High Body Mass Index or Diabetes: A Subgroup Analysis From the OASIS Trial
Oct 4-8, 2017	IDWEEK	1850	Lakota	A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration
Oct 4-8, 2017	IDWEEK	1875	Armstrong	Analysis of the Microbiological data from the Omadacycline (OMC) Phase 3 Community-Acquired Bacterial Pneumonia (CABP) Trial: The OPTIC study

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
Oct 4-8, 2017	IDWEEK	1883	Stets	A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)
Oct 4-8, 2017	IDWEEK	1885	Ohl	Efficacy and Safety of Omadacycline in Intravenous Drug Using (IVDU) and Hepatitis C-Positive (HCV+) Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A Subgroup Analysis from the OASIS Trial
Oct 4-8, 2017	IDWEEK	1886	Darpo	Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/Oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies
June 1-5, 2017	ASM Microbe	FRIDAY-239	LaPensee	Characteristics of Hospitalized Patients with ABSSSI Treated with Vancomycin at Greatest Risk for Prolonged Hospital Length of Stay in an Integrated Delivery Network (IDN)
June 1-5, 2017	ASM Microbe	FRIDAY-240	LaPensee	Patient Populations at Greatest Risk for Hospital Readmission or Repeat Emergency Department Visit within 30 Days of Hospital Discharge among Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) Treated with Vancomycin
June 1-5, 2017	ASM Microbe	SATURDAY-45	Huband	<i>In Vitro</i> Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure and Urinary Tract Pathogens Collected from the United States and Europe During the 2016 SENTRY Worldwide Surveillance Program
June 1-5, 2017	ASM Microbe	SATURDAY-46	Zhanel	<i>In Vitro</i> Antimicrobial Activity of Omadacycline, a New Aminomethylcycline, against Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Patients Attending Canadian Hospitals in 2015: The CANWARD Study
June 1-5, 2017	ASM Microbe	SATURDAY-197	LaPensee	Patient Populations at Greatest Risk for Hospital Readmission or Repeat ED Visit within 30 Days of Hospital Discharge among Hospitalized Patients with Community-Acquired Pneumonia (CABP)
June 1-5, 2017	ASM Microbe	SUNDAY-200	Overcash	Pharmacokinetics and Safety of Omadacycline in Patients with Uncomplicated Urinary Tract Infections
June 1-5, 2017	ASM Microbe	SUNDAY-201	Berg	Pharmacokinetics and Safety of the Aminomethylcycline Antibiotic Omadacycline in Subjects with Impaired Renal Function
June 1-5, 2017	ASM Microbe	SUNDAY-202	Bundrant	Safety and Pharmacokinetic Assessments of the Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple Dose Regimens
June 1-5, 2017	ASM Microbe	SUNDAY-261	Moura	Effects of Omadacycline vs Moxifloxacin on Gut Microbiota Populations and Clostridium difficile Germination, Proliferation and Toxin Production in an In Vitro Model of the Human Gut
June 1-5, 2017	ASM Microbe	SUNDAY-331	Holliday	A Multi-Site Study Comparing a Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Omadacycline Using Non-Fastidious Gram Positive Organisms
May 19-24, 2017	ATS	A3919	Gotfried	Pulmonary Concentrations of the Aminomethylcycline Antibiotic Omadacycline

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
May 19-24, 2017	ATS	A6856	Flamm	Activity of Omadacycline When Tested Against Respiratory Pathogens <i>Streptococcus Pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Moraxella catarrhalis</i> and <i>Staphylococcus aureus</i> Isolated During 2016 from Medical Centers in the USA
May 20-24, 2017	ISPOR	PRS43	Van Le	Characteristics of Hospitalized Patients With Community-Acquired Bacterial Pneumonia (CABP) at Greatest Risk for Prolonged Hospital Length of Stay in an Integrated Delivery Network
May 20-24, 2017	ISPOR	PRS44	LaPensee	Hospital Admissions Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia (CABP): Identification of Potentially Avoidable Hospital Admissions Through a Retrospective Database Analysis
Apr 22-25, 2017	ECCMID	OS0606	O’Riordan Presented by Loh	A phase 3 Randomized, Double-blind, Multi-centre Study to Compare the Safety and Efficacy of Oral and IV Omadacycline to Linezolid for Treating Adult Subjects with ABSSSI (The OASIS study)
Apr 22-25, 2017	ECCMID	P1252	O’Riordan	Efficacy of Oral and IV Omadacycline vs. Linezolid for Treating Adult Subjects With ABSSSI: Analysis by Infection Type and Pathogen in the OASIS Study
Apr 22-25, 2017	ECCMID	P1253	Huband	<i>In Vitro</i> Activity of Omadacycline and Comparators against Gram-negative Bacterial Isolates Collected from Patients in European Medical Centres (2016): Results from the SENTRY Antimicrobial Surveillance Programme
Apr 22-25, 2017	ECCMID	P1254	Dubois	<i>In Vitro</i> Extracellular and Intracellular Activity of Omadacycline against <i>Staphylococcus aureus</i>
Apr 22-25, 2017	ECCMID	P1255	O’Riordan	Efficacy of omadacycline versus linezolid in treating ABSSSI patients from different geographic regions (OASIS trial)
Apr 22-25, 2017	ECCMID	P1256	Overcash	Effects of IV/oral omadacycline versus IV/oral linezolid on lesion size and local signs of ABSSSI in the phase 3 OASIS trial
Apr 22-25, 2017	ECCMID	P1257	Gotfried	Safety and Tolerability of IV Omadacycline (OMC) and Tigecycline (TGC) in Healthy Subjects in a Study to Assess Intra-Pulmonary Steady-State Concentrations
Apr 22-25, 2017	ECCMID	P1262	Huband	<i>In vitro</i> activity of omadacycline and comparators against staphylococci, streptococci and enterococci (including resistant organism subsets) from patients in European medical centres during 2016: results from the SENTRY antimicrobial surveillance programme
Apr 22-25, 2017	ECCMID	P1263	Thwaites	The impact of non-standard test conditions on the <i>in vitro</i> activity of omadacycline by broth microdilution
Apr 22-25, 2017	ECCMID	P1264	Stapert	The <i>in vitro</i> activity of omadacycline and comparators against anaerobic bacteria
Apr 22-25, 2017	ECCMID	P1265	LaPensee	Economic impact of omadacycline among acute bacterial skin and skin structure infections (ABSSSIs) patients: cost-saving opportunities due to avoidable hospitalizations using an antibiotic with IV-to-oral switch capability

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
Apr 22-25, 2017	ECCMID	P1266	LaPensee	Cost-saving opportunities among hospitalized patients with acute bacterial skin and skin structure infections with omadacycline, a once-daily antibiotic with IV-to-oral transition capability, relative to current standard of inpatient care
Apr 22-25, 2017	ECCMID	OS1018	Horn	Comparison of Omadacycline (OMC) and Tigecycline (TGC) Pharmacodynamics (PD) in the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Subjects
Oct 26-30, 2016	IDWEEK	1827	Flamm	Activity of Omadacycline When Tested Against Gram-positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program
June 16-20, 2016	ASM Microbe	MONDAY-001	Sweeney	Activity of Omadacycline Against Clinical Isolates of Neisseria gonorrhoeae, Including Ciprofloxacin-Resistant Isolates
June 16-20, 2016	ASM Microbe	MONDAY-509	Van Wart	Population Pharmacokinetics (PPK) of Omadacycline (OMC) Following Intravenous (IV) or Oral Administration and Evaluation of Phase 3 Sparse PK Sampling Strategies
June 16-20, 2016	ASM Microbe	MONDAY-510	Van Scoy	Evaluation of the In Vitro Activity Profile of Omadacycline Against Haemophilus influenzae
June 16-20, 2016	ASM Microbe	MONDAY-512	Hinshaw	Post-antibiotic Effect of Omadacycline Against Target Pathogens
June 16-20, 2016	ASM Microbe	MONDAY-518	Villano	In Vitro Protein Binding with Omadacycline, a First in Class Aminomethylcycline Antibiotic
June 16-20, 2016	ASM Microbe	MONDAY-519	Tzanis	Effect of Food on the Bioavailability of Omadacycline in Healthy Volunteers
June 16-20, 2016	ASM Microbe	MONDAY-551	Dubois	In Vitro Intracellular Activity of Omadacycline against Legionella pneumophila
June 16-20, 2016	ASM Microbe	MONDAY-552	Diehl	In Vitro Activity of Omadacycline Against Escherichia coli Biofilms
June 16-20, 2016	ASM Microbe	MONDAY-567	Tracjewski	Omadacycline (PTK0796) Spectrum of Activity from 2003 through 2015
April 9-12, 2016	ECCMID	P1324	Chilton	Effects of omadacycline on gut microbiota populations and Clostridium difficile germination, proliferation and toxin production in an in vitro model of the human gut
April 9-12, 2016	ECCMID	P1323	Dubois	In Vitro Bacterial and Intracellular Activity of Omadacycline against Legionella pneumophila
April 9-12, 2016	ECCMID	P1317	Flamm	Omadacycline activity tested against European bacterial isolates from a combined 2010-2011 Global Surveillance program

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
April 9-12, 2016	ECCMID	P1322	Hawser	Bactericidal activity of omadacycline, a novel aminomethylcycline
April 9-12, 2016	ECCMID	P1325	Kim	Activity and Efficacy of Omadacycline against Clostridium difficile
April 9-12, 2016	ECCMID	P1318	Tanaka	Effect of Age and Gender on the Pharmacokinetics of the Oral and IV Omadacycline, A New Class of Aminomethylcyclines
April 9-12, 2016	ECCMID	P1326	Tanaka	A Pooled Analysis of Two Randomized Multicenter, Evaluator-Blind Studies Comparing the Safety and Efficacy of Omadacycline and Linezolid for the Treatment of Complicated Skin and Skin Structure Infections
April 9-12, 2016	ECCMID	P1319	Tanaka	Single and Multiple Dose Pharmacokinetics and Tolerability of Intravenous Omadacycline in Healthy Volunteers
April 9-12, 2016	ECCMID	P1320	Van Wart	Population Pharmacokinetics (PPK) of Omadacycline Following Intravenous or Oral Administration to Phase 1 Subjects
April 9-12, 2016	ECCMID	P1321	Villano	Omadacycline, an Aminomethylcycline Antibiotic, Has No Effect on QT/QTc Intervals in Healthy Subjects
Sept 17-21, 2015	ICAAC	C-554	Flamm	Activity of Omadacycline Tested against Streptococcus pneumoniae from a Global Surveillance Program (2014)
Sept 17-21, 2015	ICAAC	C-614	Flamm	Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Program (2014)
Sept 17-21, 2015	ICAAC	F-289	Flamm	Activity of Omadacycline Tested against Staphylococcus aureus from a Global Surveillance Program (2014)
Sept 17-21, 2015	ICAAC	D-194	Traczewski	Quality Control Parameters for Broth Microdilution and Agar dilution Susceptibility Tests of Omadacycline (formerly PTK-0796) against B. fragilis ATCC 25285, B. thetaiotaomicron ATCC 29741, E. lenta ATCC 43055, and C. difficile ATCC 700057 Using Fresh Media
Sept 17-21, 2015	ICAAC	D-195	Traczewski	Omadacycline (formerly PTK-0796) In Vitro Spectrum of Activity and Confirmation of Disk Mass Using Fresh Media for MIC Testing
Sept 17-21, 2015	ICAAC	D-1140	Traczewski	Quality Control Parameters for Omadacycline Minimum Inhibitory Concentration (MIC) Susceptibility Tests.
Sept 17-21, 2015	ICAAC	F-770	DuBois	In Vitro Activity of Omadacycline Against Legionella pneumophila

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
Feb 25-27, 2013	ASM Biodefense	253(G)	Draper	In Vitro Activity of Omadacycline (OMC) against Biothreat Bacteria
Sept 9-12, 2012	ICAAC	A-1282	Ting	Pharmacokinetics of Omadacycline (PTK0796) in Subjects with Hepatic Impairment
Sept 9-12, 2012	ICAAC	A-1281	Sun	Pharmacokinetics of [14C]-labeled Omadacycline (PTK 0796) in Healthy Male Subjects
Mar 31-Apr 3, 2012	ECCMID	P694	Noel	Safety and efficacy of PTK 0796 (Omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI)
Mar 31-Apr 3, 2012	ECCMID	P1422	Hanna	Metabolic Stability of PTK 0796 (Omadacycline)
Mar 31-Apr 3, 2012	ECCMID	P1423	Sun	A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects
Mar 31-Apr 3, 2012	ECCMID	P1424	Hanna	Lack of Interaction of PTK 0796 (Omadacycline) with Human Transporter
Mar 31-Apr 3, 2012	ECCMID	P1449	Flamm	Antimicrobial Activity of PTK 0796 (Omadacycline) and Comparator Agents Against Contemporary Pathogens Commonly Associated with Community-Acquired Respiratory Tract Infections Collected During 2011 from the European Union
Mar 31-Apr 3, 2012	ECCMID	P1450	Sader	Antimicrobial Activity of PTK 0796 (Omadacycline) Tested against Gram-positive Organisms Isolated from European Hospitals in 2011
Sept 17-20, 2011	ICAAC	C1-609	Ruzin	Omadacycline (PTK796) Mechanism of Action Studies by Using In Vitro Protein Synthesis Inhibition Assay and Molecular Modeling
May 7-10, 2011	ECCMID	P1528	Hait	In a Phase 2 Complicated Skin and Soft Tissue Infections Trial, Outcomes Assessed Early in the Course of Therapy were Consistent with Outcomes 10-17 Days After Completing Therapy with Either Omadacycline (OMC; PTK796) or Linezolid
May 7-10, 2011	ECCMID	P1074	Leahy	Comparative Efficacy of Omadacycline (PTK796) in Lethal Streptococcus pneumoniae and Staphylococcus aureus Pneumonia Models

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
May 7-10, 2011	ECCMID	P1141	Macone	In vitro Activity of Omadacycline (PTK796) in Broth Plus Lung Surfactant or Human Serum
Sept 12-15, 2010	ICAAC	B-069	Yu	Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model
Sept 12-15, 2010	ICAAC	C1-1413	Ruzin	Studies on the Mechanism of Resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae
Sept 12-15, 2010	ICAAC	E-1569	Biedenbach	In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe
Sept 12-15, 2010	ICAAC	E-1588	Sader	Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009
Sept 12-15, 2010	ICAAC	K-124	Ting	Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic
Sept 12-15, 2010	ICAAC	L1-1760	Macone	Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI): Results of a PTK0796 (PTK) Phase 2 Clinical Trial
Oct 25-28, 2008	ICAAC	L-1515b	Arbeit	Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in Complicated Skin and Skin Structure Infections Following IV and Oral Step Down Therapy
Sept 27-30, 2006	ICAAC	F1-1971	Smith	Antistaphylococcal Activity of MK-2764 / PTK 0796 Compared to Other Agents
Sept 27-30, 2006	ICAAC	F1-1974	Craig	In Vivo Pharmacodynamics of MK-2764 / PTK 0796 Against Various Gram-positive and Gram-negative Bacteria in the Thighs of Neutropenic and Normal Mice
Sept 27-30, 2006	ICAAC	F1-1972	DuBois	In Vitro Activity of MK-2764 / PTK 0796 Against Legionella spp.
Sept 27-30, 2006	ICAAC	F1-1973	Tessier	Pharmacokinetic/Pharmacodynamic Profile of MK-2764 / PTK 0796 against S. pneumoniae in a Murine Pneumonia Model
May 1-4, 2004	ECCMID	P926	Macone	Potent activity of BAY 73-7388, a Novel Aminomethylcycline, Against Susceptible and Resistant Gram-positive and Gram-negative Organisms
May 1-4, 2004	ECCMID	P928	Endermann	BAY 73-7388 is Highly Efficacious in Animal Models of Intraabdominal Infections Caused by a Range of Aerobic and Anaerobic Organisms, Including VRE
May 1-4, 2004	ECCMID	P930	Broetz-Oesterhelt	Superior Efficacy of BAY 73-7388, a Novel Aminomethylcycline, Compared with Linezolid and Vancomycin in Murine Sepsis Caused by Susceptible or Multiresistant Staphylococci

Posters and Oral Presentations				
Date	Conference	Presentation / Abstract Number	First Author	Title
May 1-4, 2004	ECCMID	P925	Bhatia	Activity of BAY 73-7388, a Novel Aminomethylcycline, and Other Novel Antibiotic Classes Against Resistant Bacteria In Vitro
May 1-4, 2004	ECCMID	P927	McKenney	BAY 73-7388, a Novel Aminomethylcycline, Exhibits Potent Efficacy in Pulmonary Murine Models of Infection
May 1-4, 2004	ECCMID	P929	Ladel	BAY 73-7388 Demonstrates Greater Activity than Linezolid in a Range of Murine Models of Skin and Soft Tissue Infection
May 1-4, 2004	ECCMID	P931	Endermann	BAY 73-7388, a Novel Aminomethylcycline, is Highly Active In Vivo in a Murine Model of Pneumococcal Pneumonia
Sept 14-17, 2003	ICAAC	F-751	Weir	The Mechanism of Action of PTK 0796 (BAY 73-6944)
Sept 14-17, 2003	ICAAC	F-752	Weir	The Activity of PTK 0796 (BAY 73-6944) Against Tetracycline Resistance
Sept 14-17, 2003	ICAAC	F-753	Traczewski	PTK 0796 (BAY 73-6944): In Vitro Potency and Spectrum of Activity Compared to Ten Other Antimicrobial Compounds
Sept 14-17, 2003	ICAAC	F-754	Macone	In Vitro Activity of PTK 0796 (BAY 73-6944) Against Gram-Positive and Gram-Negative Organisms
Sept 14-17, 2003	ICAAC	F-755	Bhatia	PTK 0796 (BAY 73-6944) and other Novel Tetracycline Derivatives Exhibiting Potent in vitro and in vivo Activities Against Antibiotic Resistant Gram-Positive Bacteria
Sept 14-17, 2003	ICAAC	F-756	Traczewski	PTK 0796 (BAY 73-6944): Effects of Environmental Variation on MICs and Confirmation of Disk Mass
Sept 14-17, 2003	ICAAC	F-757	McKenney	Evaluation of PTK 0796 (BAY 73-6944) in Experimental Models of Infections Caused by Gram-Positive and Gram-Negative Pathogens
Sept 14-17, 2003	ICAAC	F-758	McKenney	The Efficacy of PTK 0796 (BAY 73-6944) in Murine Models of Streptococcus pneumoniae Infections
Sept 14-17, 2003	ICAAC	F-759	Cannon	Pharmacokinetics of PTK 0796 (BAY 73-6944) in Mouse, Rat and Cynomolgus Monkey
Sept 14-17, 2003	ICAAC	F-760	Chaturvedi	In Vitro Assessment of Plasma Protein Binding and Metabolic Stability of PTK 0796 (BAY 73-6944)